All In Biotech

Drug Trial Radar · NCT06568471

A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

Last checked: Nov 20, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Nov 16, 2024

Primary completion

Feb 2026

Study completion May 2026

Sponsor

Sponsor type
Industry
First posted
Aug 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized study is to assess LDL-C reductions at Week 12 with monthly (Q4W \[≤31 days\]) dosing of HST101 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with atherosclerotic cardiovascular disease (ASCVD) or very-high/high risk for ASCVD including Heterozygous familial hypercholesterolemia (HeFH) on a stable diet and oral LDL-C lowering drug therapy, followed by 36-week open-label treatment with subsequent 4-week follow-up for total 52-week long-term safety and efficacy evaluation.

Conditions

  • Hypercholesterolemia
  • Dyslipidemias
  • Primary Hypercholesterolemia
  • Heterozygous Familial Hypercholesterolemia
  • Hyperlipidemia; Mixed
  • Metabolic Disease
  • ASCVD

Interventions

  • LerodalcibepDrug

    PCSK9 inhibitor

  • matching placeboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. LDL-C change compared to PlaceboTime frame: 12 weeks
  2. Mean LDL-C change at Weeks 10 and 12 compared to PlaceboTime frame: 12 weeks

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China · Not yet recruiting

  • Beijing Anzhen Hospital of Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Luhe Hospital, Capital Medical Univeristy

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Tsinghua Changgeng Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Fuwai Hospital, CAMS & PUMC

    Beijing, Beijing Municipality, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • Shijiazhuang People's Hospital

    Shijiazhuang, Hebei, China · Recruiting

  • Daqingshi People's Hospital

    Daqing, Heilingjiang, China · Recruiting

  • The 2nd Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Nanchang People's Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Binzhou Medical University Hospital

    Binzhou, Shandong, China · Recruiting

  • Heze Municipal Hospital

    Heze, Shandong, China · Recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Recruiting

  • Zibo Municipal Hospital

    Zibo, Shandong, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Tianjin People's Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical Univesity

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.